These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 11479456

  • 1. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
    Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E.
    Am Heart J; 2001 Aug; 142(2):211-7. PubMed ID: 11479456
    [Abstract] [Full Text] [Related]

  • 2. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW, Ferguson JJ.
    Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [Abstract] [Full Text] [Related]

  • 3. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ.
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ, Califf RM.
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [Abstract] [Full Text] [Related]

  • 13. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    MICHELANGELO OASIS 5 Steering Committee, Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, Budaj A, Joyner C, Chrolavicius S, Fox KA.
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [Abstract] [Full Text] [Related]

  • 14. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
    de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM, Braunwald E, Investigators.
    Eur Heart J; 2004 Oct; 25(19):1688-94. PubMed ID: 15451146
    [Abstract] [Full Text] [Related]

  • 15. Reducing cardiac events after acute coronary syndromes.
    Granger CB, Weaver WD.
    Rev Cardiovasc Med; 2004 Oct; 5 Suppl 5():S39-46. PubMed ID: 15619614
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR.
    J Am Coll Cardiol; 2009 Jul 28; 54(5):468-76. PubMed ID: 19628124
    [Abstract] [Full Text] [Related]

  • 17. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
    Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, Jang IK, Januzzi JL, PRISM-PLUS trial.
    Am J Cardiol; 2004 Apr 01; 93(7):843-7. PubMed ID: 15050486
    [Abstract] [Full Text] [Related]

  • 18. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E, Cakmak M, Tartan Z, Cam N.
    Heart Vessels; 2003 Jul 01; 18(3):117-22. PubMed ID: 12955426
    [Abstract] [Full Text] [Related]

  • 19. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E.
    Circulation; 2004 Feb 24; 109(7):874-80. PubMed ID: 14757697
    [Abstract] [Full Text] [Related]

  • 20. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
    Mehta RH, Greenbaum AB, Lokhnygina Y, Newby LK, Van De Werf F, Armstrong PW, Pieper KS, Califf RM, Granger CB, Harrington RA.
    J Interv Cardiol; 2007 Oct 24; 20(5):299-306. PubMed ID: 17880325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.